Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancerOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared fecal microbiome and metabolome profiles between 50 colorectal cancer (CRC) patients and 50 healthy volunteers. The goal was to find noninvasive microbial and metabolic signatures linked to CRC.
How was it studied?
Fecal samples underwent 16S rRNA gene sequencing for microbiome profiling and gas chromatography-mass spectrometry (GC-MS) for metabolome profiling. Microbiome and metabolome datasets were then integrated using correlation and multivariate analyses.
What did they find?
CRC patients showed lower bacterial diversity, with 1,084 OTUs total and 76 discriminatory OTUs separating the groups. The CRC group had elevated polyamines, cadaverine and putrescine, which correlated with CRC-associated microbes; cadaverine yielded an AUC of 0.764 and putrescine an AUC of 0.672 for distinguishing CRC from healthy samples.
Why it matters
The findings suggest gut microbes and their metabolites, particularly polyamines, interact in ways that are disrupted in CRC. These microbe-associated metabolites could serve as noninvasive diagnostic biomarkers pending further validation.